Neuroscientist Alleges Irregularities in Alzheimer’s Research

A US neuroscientist claims that some of the studies of the experimental agent, Simufilam, a drug that targets amyloid beta in Alzheimer's disease, are flawed and has taken his concerns to the NIH.
Medscape Medical News